-
Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
September 17, 2026 — Bayer today announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated… Source: Read More
-
Novo Nordisk Provides Update on ZEUS Phase 3 Trial for Ziltivekimab
A New Approach to Cardiovascular Risk Novo Nordisk recently released an update regarding the ZEUS Phase 3 clinical trial, which is investigating the efficacy of ziltivekimab. This trial focuses on patients suffering from both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), a population with significant unmet medical needs. Understanding the ZEUS Trial The…